Thanks...i wasn't sure either. So it might be that it has overshot a bit ? And dividend correction today as well.
Good way to compare them tho. Appreciate seeing the data.
Printable View
Geoff has a unique set of experiences as a senior executive and prudential
regulator in Australia and internationally. He has held senior financial
services executive roles in NAB, was CEO of Suncorp's Life and Wealth
businesses in Australia and New Zealand, and most recently he was a board
member of the Australian Prudential Regulation Authority (APRA).
Internationally he served as an executive committee member on the insurance
global standard setting body, International Association of Insurance
Supervisors (IAIS), where he chaired the Audit and Risk Committee. Geoff is
recognised as a global leader on climate change financial risk through his
regulatory work at APRA, IAIS and the UN Environment Programme where he
chaired the Sustainable Insurance Forum.
HGH has flagged its strategy to grow its Australian business and is pleased
to boost its director capability with Geoff's commercial and regulatory
experience.
Are they flagging as in highlighting or giving up??
Jarden recently updated their target price to $2.46 and reiterated their BUY rating.
This is consistent with this mutts view that HGH is headed to $2.50 in 2022.
this stock always back fills gains after moving up since april 2020, probably do the same again. Stunning chart.
Recovered most of divvy amount.
DRP price $2.27125669
Wasn’t it really $2.271256698734
Jeff, if you going to be exact do it properly